The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Lilly; MSD Oncology; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft; Gemeinsamer Bundesausschuss
 
Daniel Wilhelm Mueller
No Relationships to Disclose
 
Mohammad-Reza Rafiyan
No Relationships to Disclose
 
Dragan Kiselicki
No Relationships to Disclose
 
Regina Eickhoff
No Relationships to Disclose
 
Elke Jaeger
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma